Ronald Hebert, MD
Family Medicine · Lafayette, LANPI 1003310897
Payments from drug & device makers
Across 332 payments — averaging $15.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$759
- Novo Nordisk$572
- AbbVie$520
- Lilly USA, LLC$338
- Astellas Pharma US Inc$315
- Amgen$313
- plus $2K from 32 others
What the payments were for
- Food & beverage$5,15698%
- Education$1062%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 45 | $759 |
| Novo Nordisk | 42 | $572 |
| AbbVie | 39 | $520 |
| Lilly USA, LLC | 21 | $338 |
| Astellas Pharma US Inc | 14 | $315 |
| Amgen | 22 | $313 |
| GSK | 19 | $307 |
| Merck | 15 | $248 |
| Bayer | 15 | $240 |
| Corium, LLC | 18 | $235 |
| Sanofi-aventis U.S. LLC | 10 | $178 |
| Esperion Therapeutics, Inc. | 9 | $123 |
| Boehringer Ingelheim | 7 | $110 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $108 |
| Dexcom, Inc. | 3 | $91 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $87 |
| Pfizer | 4 | $65 |
| Sumitomo Pharma America, Inc. | 4 | $64 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $62 |
| Phathom Pharmaceuticals, Inc. | 4 | $61 |
| Kowa Pharmaceuticals America, Inc. | 2 | $52 |
| Noven Therapeutics, LLC | 2 | $45 |
| Novartis | 3 | $45 |
| Abbott | 2 | $35 |
| Lundbeck LLC | 1 | $30 |
| Idorsia Pharmaceuticals US Inc | 2 | $28 |
| Arbor Pharmaceuticals, Inc. | 2 | $27 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| Ironshore Pharmaceuticals Inc. | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Exact Sciences | 1 | $20 |
| Antares Pharma, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $19 |
| Seqirus USA Inc | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Bausch Health US, LLC | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $13 |
How this compares
$5,262 in reported general payments places this provider in the 80th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 158 | $200,313 |
| OzempicSemaglutide | 87 | $103,165 |
| EnbrelEtanercept | 13 | $90,740 |
| EliquisApixaban | 79 | $66,130 |
| FarxigaDapagliflozin Propanediol | 50 | $49,764 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 61 | $47,363 |
| TrulicityDulaglutide | 37 | $44,962 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $41,955 |
| JardianceEmpagliflozin | 34 | $29,230 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 33 | $27,908 |
| JanuviaSitagliptin Phosphate | 21 | $21,711 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 46 | $21,526 |
| LinzessLinaclotide | 25 | $20,987 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 23 | $19,839 |
| XareltoRivaroxaban | 21 | $15,824 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $338 | $245,276195 claims |
| Novo NordiskOzempic | $572 | $103,16587 claims |
| AmgenEnbrel | $313 | $90,74013 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $759 | $77,67283 claims |
| PfizerEliquis | $65 | $66,13079 claims |
| GSKTrelegy Ellipta, Shingrix | $307 | $54,09091 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $110 | $34,25045 claims |
| MerckJanuvia | $248 | $21,71121 claims |
| AbbVieLinzess | $520 | $20,98725 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $178 | $19,83923 claims |
| NovartisEntresto | $45 | $13,38112 claims |
| Astellas Pharma US IncMyrbetriq | $315 | $12,02815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Lafayette
- Patrick MooreLafayette$32K
- Clinton GuilloryMonroe$18.5M
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
- William NaboursLake Charles$3M
- Ramon VargasKenner$2.1M
- Stephen JonesNew Orleans$513K
- Joshua WhatleyLake Charles$366K
- Richard JeansonneMandeville$362K
- Kristen ThomasNew Orleans$361K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.